Interferon-alpha (IFN-α) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway

被引:0
作者
Kaser, A [1 ]
Enrich, B [1 ]
Ludwiczek, O [1 ]
Vogel, W [1 ]
Tilg, H [1 ]
机构
[1] Univ Innsbruck Hosp, Dept Med, Div Gastroenterol & Hepatol, A-6020 Innsbruck, Austria
关键词
interferon-alpha; hepatitis C infection; cytotoxicity; perforin; Fas ligand;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cell-mediated cytotoxicity is exerted via perforin and Fas ligand (FasL). We have recently shown that IFN-alpha up-regulates Fast expression in T cells isolated from healthy volunteers and augments activation-induced T cell death. Since the Fas/FasL system is implicated in the pathogenesis of hepatic failure and both molecules have been shown to be up-regulated in hepatitis C virus (HCV) infection, we studied whether cytotoxicity via the Fast system is enhanced by IFN-alpha and therefore could contribute to hepatic injury. We investigated Fast and perforin expression in peripheral blood mononuclear cells (PBMC) derived from HCV+ donors by Northern analysis and soluble Fast synthesis by ELISA. Natural killer (NK) cell and cytotoxic T lymphocyte (CTL) cytotoxicity was studied by Cr-51-release assays. IFN-alpha up-regulates Fast mRNA and protein synthesis in mitogen-activated PBMC of HCV+ individuals, as previously found in healthy subjects. Stimulation with IFN-alpha increases perforin mRNA levels in PBMC. In NK cytotoxicity assays, the enhancement of cytotoxicity by IFN-alpha is mainly due to the perforin pathway, while the Fast pathway plays only a minor role. In CTL cytotoxicity experiments neither the Fast nor the perforin pathway is further enhanced by IFN-alpha. Our data suggest that upregulation of perforin by IFN-alpha results in elevated cytotoxicity, suggesting that IFN-alpha might support elimination of virally infected cells via this pathway. In contrast, the major effect of IFN-alpha on the Fas/FasL system might be the enhanced elimination of activated T cells as a means of finally limiting a T cell response.
引用
收藏
页码:71 / 77
页数:7
相关论文
共 50 条
  • [41] PRIMARY BILIARY-CIRRHOSIS INDUCED BY INTERFERON-ALPHA THERAPY FOR HEPATITIS-C VIRUS-INFECTION
    DAMICO, E
    PAROLI, M
    FRATELLI, V
    PALAZZI, C
    BARNABA, V
    CALLEA, F
    CONSOLI, G
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (10) : 2113 - 2116
  • [42] Renal failure associated with hepatitis C virus infection - Improvement in renal function after treatment with interferon-alpha
    Moses, PL
    Krawitt, EL
    Aziz, W
    Corwin, HL
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (02) : 443 - 446
  • [43] DETECTION OF INTERFERON-ALPHA EXPRESSION BY PCR IN PATIENTS WITH CHRONIC HEPATITIS-C AND HEPATITIS NON-A, NON-B
    BRANDT, ER
    DEVENISH, RJ
    HERTZOG, PJ
    DUDLEY, FJ
    LINNANE, AW
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1994, 9 (04) : 373 - 380
  • [44] SERIAL DENSITY ANALYSIS OF HEPATITIS-C VIRUS PARTICLE-POPULATIONS IN CHRONIC HEPATITIS-C PATIENTS TREATED WITH INTERFERON-ALPHA
    KANTO, T
    HAYASHI, N
    TAKEHARA, T
    HAGIWARA, H
    MITA, E
    OSHITA, M
    KATAYAMA, K
    KASAHARA, A
    FUSAMOTO, H
    KAMADA, T
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1995, 46 (03) : 230 - 237
  • [45] Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial
    Kiso, S
    Kawata, S
    Tamura, S
    Imai, Y
    Inui, Y
    Nagase, T
    Maeda, Y
    Yamasaki, E
    Tsushima, H
    Igura, T
    Himeno, S
    Seki, K
    Matsuzawa, Y
    [J]. JOURNAL OF GASTROENTEROLOGY, 1997, 32 (01) : 56 - 62
  • [46] A Biopsychosocial Model of Interferon-Alpha-Induced Depression in Patients with Chronic Hepatitis C Infection
    Baranyi, Andreas
    Meinitzer, Andreas
    Stepan, Alexandra
    Putz-Bankuti, Csilla
    Breitenecker, Robert J.
    Stauber, Rudolf
    Kapfhammer, Hans-Peter
    Rothenhaeusler, Hans-Bernd
    [J]. PSYCHOTHERAPY AND PSYCHOSOMATICS, 2013, 82 (05) : 332 - 340
  • [47] Cutaneous, pulmonary and hepatic sarcoidosis associated with autoimmune complications during interferon-alpha treatment for hepatitis C virus infection
    Akay, BN
    Ekmekci, P
    Sanli, H
    Celik, G
    Bozdayi, M
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2006, 20 (04) : 442 - 445
  • [48] PRELIMINARY-RESULTS OF TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALPHA IN RENAL-TRANSPLANT PATIENTS
    ROSTAING, L
    IZOPET, J
    BARON, E
    DUFFAUT, M
    PUEL, J
    DURAND, D
    SUC, JM
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 : 93 - 96
  • [49] A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naive patients with chronic hepatitis C
    Tassopoulos, NC
    Ketikoglou, I
    Tsantoulas, D
    Raptopoulou, M
    Hatzis, G
    Vafiadis, I
    Sidiropoulos, L
    Kanatakis, S
    Anagnostopoulos, G
    Sypsa, V
    Hatzakis, A
    [J]. JOURNAL OF VIRAL HEPATITIS, 2003, 10 (05) : 383 - 389
  • [50] Interferon-alpha plus indomethacin combined therapy in HBeAg positive chronic hepatitis B non-responder to a previous IFN alpha course: Results of a pilot study
    Andreone, P
    Cursaro, C
    Gramenzi, A
    Miniero, R
    Bernardi, M
    Gasbarrini, G
    [J]. INTERNATIONAL HEPATOLOGY COMMUNICATIONS, 1996, 5 (03): : 151 - 159